Sherbrooke Park Advisers’s Medifast MED Stock Holding History

Sherbrooke Park Advisers’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-23,858	Closed	-$521K	–	1120
2024 Q2	$521K	Buy	+23,858	New	+$636K	0.09%	393

Other funds holding MED

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sherbrooke Park Advisers's MED Position: Q3 2024 in Review

Sherbrooke Park Advisers sold out of Medifast (MED) in Q3 2024, closing a stake of 23,858 shares — an estimated $521K sold.

Sherbrooke Park Advisers first reported a position in MED in Q2 2024 and held it in 1 quarter. The position peaked at $521K in Q2 2024. 140 funds tracked by Wall St. Rank hold MED as of Q3 2024.

Sherbrooke Park Advisers reported no remaining Medifast position as of Q3 2024 after selling out during the quarter.
Sherbrooke Park Advisers sold 23,858 Medifast shares in Q3 2024, an estimated $521K.
Sherbrooke Park Advisers first reported a position in Medifast in Q2 2024 and held it in 1 quarter.
Sherbrooke Park Advisers's Medifast position peaked at $521K in Q2 2024.
140 funds tracked by Wall St. Rank held Medifast as of Q3 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.